不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤一线治疗的新见解：我们是否在改善结局？
英文原题：New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?
查看英文原题
New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是最常见的淋巴瘤亚型，包含生物学和临床特征各异的异质性患者亚群。利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松联合方案（R-CHOP）一直是标准初始治疗，可使超过60%的晚期患者获得持久缓解。过去二十年来，多种旨在提高该方案疗效的尝试收效有限。近期淋巴瘤治疗领域涌现出多种新型疗法并显示良好结果，包括小分子药物、新型单克隆抗体、抗体药物偶联物（ADC）、双特异性抗体（BsAb）和嵌合抗原受体（CAR）T细胞疗法。本文综述DLBCL治疗策略的近期进展及其对患者初始治疗管理的潜在影响。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success.
Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results. These include small molecules, novel monoclonal antibodies, antibody-drug conjugates (ADC), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapy. This review explores recent advancements in therapeutic strategies for DLBCL and their potential impact on the initial management of DLBCL patients.
论文信息
- 作者
- Abrisqueta P
- 单位
- Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.Spain
- 文献类型
- 综述
- 期刊
- Journal of clinical medicine2024 Mar 27
- 原文标识
- PubMed 38610693 · DOI 10.3390/jcm13071929
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →